Latest News
Marlowe trading strongly as it sets out new goals
Business software and services company Marlowe said on Tuesday that trading in its second half remained “strong”, with results for the year ending 31 March expected to be at the top end of current market expectations.
Asia report: Markets mixed as Japan exports rise
Markets in Asia closed in a mixed state on Wednesday, as investors digested the latest export data from Japan, while bourses in mainland China remained on holiday.
Pfizer-BioNTech to supply EU with additional 200m doses of Covid-19 vaccine
Pfizer and BioNTech have agreed to supply the European Union with an additional 200 million doses of their Covid-19 vaccine.
Stamp duty break drives 8.5% annual house price jump
UK house prices rose 8. 5% in 2021 as the chancellor's stamp duty holiday spurred a boom in property purchases, official figures showed.
Carnival readies Costa Cruises vessels for March sailings
Cruise operator Carnival said on Wednesday that its Italian subsidiary was ready to set sail again after having enhanced both health and safety protocols.
EU car sales plunge to record January low
EU car registrations plunged to a record low for January as Covid-19 restrictions and economic uncertainty weighed heavily on sales.
British American Tobacco profit rises thanks to better price mix
British American Tobacco reported adjusted revenue of £25. 78bn on Wednesday, up 3. 3%, as the company “absorbed” an estimated 2. 5% headwind from the Covid-19 pandemic.
Creo Medical ends year 'marginally ahead' of forecasts
Medical devices company Creo Medical Group said on Wednesday that trading for 2020 was “marginally ahead” of management expectations, with revenue rising to more than £9m, from £0. 01m in 2019.
ECSC secures two 'significant contract wins'
Cybersecurity services provider ECSC Group said on Wednesday that it had secured two "significant contract wins" in its managed detection and response division with an unnamed "major" UK charity and a mystery leisure group.
Synectics wins new contracts with Ireland's National Transport Authority
Security and surveillance systems group Synectics said on Wednesday that it has recently been awarded several new contracts for the Irish Republic's National Transport Authority.
Costain settles dispute over Welsh motorway
Costain has agreed a settlement with the Welsh government over their long-running dispute about the troubled A465 motorway project.
London open: Stocks edge lower after inflation data
London stocks edged lower in early trade on Wednesday as investors mulled an unexpected uptick in UK inflation.
Rio Tinto delivers record dividend as iron ore demand boosts profits
Rio Tinto delivered a record dividend to shareholders as soaring iron ore prices and demand from China drove full-year profits sharply higher.
Peter Hargreaves sells £300m of Hargreaves Lansdown shares
Peter Hargreaves has sold £300m of shares in Hargreaves Lansdown, leaving him owning less than 20% of the company he co-founded 30 years ago.
Ceres Power trades well through end of 2020
Fuel cell technology company Ceres Power updated the market on its trading on Wednesday, reporting that revenue and other operating income for the 18 months ended 31 December would be above market expectations at around £32m to £33m.
TI Fluid CEO Bill Kozyra to step down
TI Fluid Systems' chief executive Bill Kozyra will step down later this year and hand over to company insider Hans Dieltjens.
UK inflation ticks higher in January as food prices rise
UK inflation unexpectedly ticked higher in January amid a rise in the price of food and household goods, according to figures released on Wednesday by the Office for National Statistics.
IP Group portfolio business acquired by Centessa
Business development outfit IP Group said on Wednesday that portfolio company ApcinteX had been acquired by Centessa Pharmaceuticals following a $250. 0m financing round.
Imperial Brands appoints Lukas Paravicini as new CFO
Imperial Brands has appointed Lukas Paravicini as its new chief financial officer, with Oliver Tant due to step down after seven years in the role.
AstraZeneca's breast cancer drug moves to early primary analysis
AstraZeneca said the phase 3 trial for breast cancer drug Lynparza would move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).